NIKKI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NIKKI (NIKKI).
NIKKI is a combination oral contraceptive containing ethinyl estradiol and drospirenone. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropin release, thereby inhibiting ovulation.
| Metabolism | Ethinyl estradiol is metabolized primarily via cytochrome P450 3A4 (CYP3A4) and undergoes first-pass metabolism in the gut and liver. Drospirenone is metabolized primarily via CYP3A4 and also undergoes sulfation and glucuronidation. |
| Excretion | Renal: 50% (20% unchanged, 30% as metabolites); Fecal: 40%; Biliary: 10% |
| Half-life | Terminal elimination half-life: 12-15 hours; clinical context: allows once-daily dosing; steady-state reached in ~3 days |
| Protein binding | 97% bound to albumin and sex hormone-binding globulin |
| Volume of Distribution | 2.5 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 88%; Transdermal: 60% |
| Onset of Action | Oral: 1-2 hours; Transdermal: 6-12 hours |
| Duration of Action | Oral: 24 hours (once-daily dosing); Transdermal: 7 days (weekly patch) |
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 days of placebo.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with GFR < 30 mL/min/1.73 m² due to risk of hyperkalemia. For GFR 30-49 mL/min/1.73 m², consider alternative contraception. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment) due to altered steroid metabolism. |
| Pediatric use | Not indicated for use before menarche. For postmenarchal adolescents, dose same as adult: one active tablet daily for 21 days, then placebo for 7 days. |
| Geriatric use | Not indicated for postmenopausal women; no geriatric-specific dosing established. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NIKKI (NIKKI).
| Breastfeeding | Breastfeeding safety: Not recommended. Combined hormonal contraceptives may reduce milk production and quality. Small amounts of estrogens and progestins are excreted in breast milk; M/P ratio not specifically documented for this combination. Alternative contraception is preferred. |
| Teratogenic Risk | NIKKI (estradiol/norethindrone, a combined hormonal contraceptive). Pregnancy category X. First trimester: known teratogen; risk of congenital defects (e.g., congenital heart defects, limb reduction defects) if inadvertently exposed. Second and third trimesters: associated with fetal harm, including feminization of male fetuses (due to androgenic effects of progestin) and possible genitourinary abnormalities. Use is contraindicated in pregnancy. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","History of deep vein thrombosis or pulmonary embolism","Cerebrovascular or coronary artery disease","Current or history of migraine with focal neurological symptoms","Diabetes with vascular involvement","Uncontrolled hypertension","Known or suspected pregnancy","Undiagnosed abnormal uterine bleeding","Breast cancer or other estrogen-sensitive cancer","Hepatic tumors or active liver disease","Hypersensitivity to any component","Renal insufficiency (creatinine clearance < 30 mL/min)","Adrenal insufficiency","Cigarette smoking in women over 35 years of age"]
| Precautions | ["Thrombotic disorders (e.g., venous thromboembolism, arterial thromboembolism)","Cardiovascular disease (e.g., myocardial infarction, stroke)","Elevated blood pressure","Hyperkalemia (especially in patients with renal insufficiency or on drugs that increase potassium)","Liver disease","Gallbladder disease","Carbohydrate and lipid metabolism effects","Headache/migraine","Bleeding irregularities","Depression","Carcinoma of the breast and reproductive organs","Hereditary angioedema"] |
Loading safety data…
| Fetal Monitoring | Before initiating: rule out pregnancy (β-hCG). During use: monitor for signs of venous thromboembolism, hypertension, liver function abnormalities, and gallstone formation. If inadvertent pregnancy occurs, discontinue immediately and consider prenatal diagnostics (e.g., ultrasound, amniocentesis). |
| Fertility Effects | NIKKI suppresses ovulation, thereby preventing pregnancy. Upon discontinuation, ovulation typically resumes within 1-3 months. No long-term negative impact on fertility; normal fecundity returns after cessation. |